Richard B Warren

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/3793200/publications.pdf

Version: 2024-02-01

245 papers	10,713 citations	31902 53 h-index	42291 92 g-index
260 all docs	260 docs citations	260 times ranked	10309 citing authors

#	Article	IF	Citations
1	A genome-wide association study identifies new psoriasis susceptibility loci and an interaction between HLA-C and ERAP1. Nature Genetics, 2010, 42, 985-990.	9.4	918
2	Identification of 15 new psoriasis susceptibility loci highlights the role of innate immunity. Nature Genetics, 2012, 44, 1341-1348.	9.4	848
3	Differential Drug Survival of Biologic Therapies for the Treatment of Psoriasis: A Prospective Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2015, 135, 2632-2640.	0.3	318
4	British Association of Dermatologists guidelines for biologic therapy for psoriasis 2017. British Journal of Dermatology, 2017, 177, 628-636.	1.4	226
5	Incidence of Cardiovascular Disease in Individuals with Psoriasis: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2013, 133, 2340-2346.	0.3	224
6	Psoriasis: is the impairment to a patientâ€™s life cumulative?. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 989-1004.	1.3	180
7	The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases. Rheumatology, 2014, 53, 213-222.	0.9	177
8	Identification of ZNF313 / RNF114 as a novel psoriasis susceptibility gene. Human Molecular Genetics, 2008, 17, 1938-1945.	1.4	176
9	Bimekizumab versus Secukinumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 142-152.	13.9	173
10	Clinical and genetic differences between pustular psoriasis subtypes. Journal of Allergy and Clinical Immunology, 2019, 143, 1021-1026.	1.5	165
11	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. Nature Communications, 2015, 6, 6046.	5.8	149
12	Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Lancet, The, 2021, 397, 487-498.	6.3	139
13	Factors associated with adverse COVID-19 outcomes in patients with psoriasisâ€”insights from a global registryâ€“based study. Journal of Allergy and Clinical Immunology, 2021, 147, 60-71.	1.5	136
14	Comparison of three screening tools to detect psoriatic arthritis in patients with psoriasis (CONTEST) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	1.4	130
15	HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis. Journal of Allergy and Clinical Immunology, 2019, 143, 2120-2130.	1.5	128
16	A consensus report on appropriate treatment optimization and transitioning in the management of moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2014, 28, 438-453.	1.3	122
17	Bimekizumab in patients with active psoriatic arthritis: results from a 48-week, randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial. Lancet, The, 2020, 395, 427-440.	6.3	122
18	Efficacy and safety of risankizumab vs. secukinumab in patients with moderateâ€toâ€severe plaque psoriasis (IMMerge): results from a phase III, randomized, openâ€label, efficacyâ€“assessorâ€blinded clinical trial*. British Journal of Dermatology, 2021, 184, 50-59.	1.4	119

#	Article	IF	Citations
19	A Review of Biologic Therapies Targeting IL-23 and IL-17 for Use in Moderate-to-Severe Plaque Psoriasis. Dermatology and Therapy, 2016, 6, 1-12.	1.4	118
20	Assessing the relative efficacy of interleukin-17 and interleukin-23 targeted treatments for moderate-to-severe plaque psoriasis: A systematic review and network meta-analysis of PASI response. PLoS ONE, 2019, 14, e0220868.	1.1	118
21	Association between psoriasis and inflammatory bowel disease: a Danish nationwide cohort study. British Journal of Dermatology, 2016, 175, 487-492.	1.4	114
22	Bimekizumab versus Adalimumab in Plaque Psoriasis. New England Journal of Medicine, 2021, 385, 130-141.	13.9	114
23	Cumulative life course impairment in psoriasis: patient perception of disease-related impairment throughout the life course. British Journal of Dermatology, 2011, 164, 1-14.	1.4	113
24	Pregnancy Outcomes in the Tofacitinib Safety Databases for Rheumatoid Arthritis and Psoriasis. Drug Safety, 2016, 39, 755-762.	1.4	112
25	Genetic Variation in Efflux Transporters Influences Outcome to Methotrexate Therapy in Patients with Psoriasis. Journal of Investigative Dermatology, 2008, 128, 1925-1929.	0.3	109
26	The British Association of Dermatologistsâ€™ Biologic Interventions Register (BADBIR): design, methodology and objectives. British Journal of Dermatology, 2012, 166, 545-554.	1.4	108
27	Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 2017, 137, 1646-1654.	0.3	108
28	Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trials. British Journal of Dermatology, 2017, 176, 890-901.	1.4	107
29	Longâ€term efficacy and safety of tildrakizumab for moderateâ€toâ€severe psoriasis: pooled analyses of two randomized phase <scp>III</scp> clinical trials (re <scp>SURFACE</scp> 1 and re <scp>SURFACE</scp> 2) through 148 weeks. British Journal of Dermatology, 2020, 182, 605-617.	1.4	103
30	An intensified dosing schedule of subcutaneous methotrexate in patients with moderate to severe plaque-type psoriasis (METOP): a 52 week, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet, The, 2017, 389, 528-537.	6.3	94
31	Clinical Utility of Random Antiâ€“Tumor Necrosis Factor Drugâ€“Level Testing and Measurement of Antidrug Antibodies on the Longâ€Term Treatment Response in Rheumatoid Arthritis. Arthritis and Rheumatology, 2015, 67, 2011-2019.	2.9	90
32	Psoriasis treat to target: defining outcomes in psoriasis using data from a realâ€world, populationâ€based cohort study (the British Association of Dermatologists Biologics and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 217 Td	1.4	88
33	Demographics and disease characteristics of patients with psoriasis enrolled in the <scp>B</scp> ritish <scp>A</scp> ssociation of <scp>D</scp> ermatologists <scp>B</scp> iologic <scp>I</scp> nterventions <scp>R</scp> egister. British Journal of Dermatology, 2015, 173, 510-518.	1.4	87
34	British Association of Dermatologistsâ€™ guidelines for the safe and effective prescribing of methotrexate for skin disease 2016. British Journal of Dermatology, 2016, 175, 23-44.	1.4	86
35	Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trials. Journal of the American Academy of Dermatology, 2017, 76, 441-448.e2.	0.6	86
36	Association Between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death Among Patients With Immune-Mediated Inflammatory Disease and COVID-19. JAMA Network Open, 2021, 4, e2129639.	2.8	86

#	Article	IF	Citations
37	Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). British Journal of Dermatology, 2020, 183, 294-302.	1.4	85
38	Clinical use of dimethyl fumarate in moderateâ€toâ€severe plaqueâ€type psoriasis: a European expert consensus. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 3-14.	1.3	76
39	Polymorphisms in the IL-12Î² and IL-23R Genes Are Associated with Psoriasis of Early Onset in a UK Cohort. Journal of Investigative Dermatology, 2008, 128, 1325-1327.	0.3	74
40	Assessment and management of methotrexate hepatotoxicity in psoriasis patients: report from a consensus conference to evaluate current practice and identify key questions toward optimizing methotrexate use in the clinic. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 758-764.	1.3	74
41	Comparison of Drug Discontinuation, Effectiveness, and Safety Between Clinical Trial Eligible and Ineligible Patients in BADBIR. JAMA Dermatology, 2018, 154, 581.	2.0	74
42	Identifying demographic, social and clinical predictors of biologic therapy effectiveness in psoriasis: a multicentre longitudinal cohort study. British Journal of Dermatology, 2019, 180, 1069-1076.	1.4	74
43	Differential Drug Survival of Second-Line Biologic Therapies in Patients with Psoriasis: Observational Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 775-784.	0.3	71
44	Secukinumab in pregnancy: outcomes in psoriasis, psoriatic arthritis and ankylosing spondylitis from the global safety database. British Journal of Dermatology, 2018, 179, 1205-1207.	1.4	69
45	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. Annals of the Rheumatic Diseases, 2011, 70, 1016-1019.	0.5	68
46	Systemic therapies for psoriasis: methotrexate, retinoids, and cyclosporine. Clinics in Dermatology, 2008, 26, 438-447.	0.8	67
47	Outcomes of methotrexate therapy for psoriasis and relationship to genetic polymorphisms. British Journal of Dermatology, 2009, 160, 438-441.	1.4	64
48	Safety of selective <scp>IL</scp>â€23p19 inhibitors for the treatment of psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, 1676-1684.	1.3	64
49	Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis. Journal of Investigative Dermatology, 2016, 136, 1584-1591.	0.3	63
50	Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: AÂProspective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). Journal of Investigative Dermatology, 2018, 138, 534-541.	0.3	62
51	Methotrexate for psoriasis in the era of biological therapy. Clinical and Experimental Dermatology, 2008, 33, 551-554.	0.6	61
52	Brodalumab in psoriasis: evidence to date and clinical potential. Drugs in Context, 2019, 8, 1-11.	1.0	61
53	Efficacy of ixekizumab compared to etanercept and placebo in patients with moderateâ€toâ€severe plaque psoriasis and nonâ€pustular palmoplantar involvement: results from three phase 3 trials (<scp>UNCOVER</scp>â€1, <scp>UNCOVER</scp>â€2 and <scp>UNCOVER</scp>â€3). Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1686-1692.	1.3	60
54	Defining the Therapeutic Range for AdalimumabÂand Predicting Response in Psoriasis: A Multicenter Prospective Observational Cohort Study. Journal of Investigative Dermatology, 2019, 139, 115-123.	0.3	60

#	Article	IF	Citations
55	Genetic susceptibility to psoriasis and psoriatic arthritis: implications for therapy. British Journal of Dermatology, 2012, 166, 474-482.	1.4	59
56	Reduction in skin cancer diagnosis, and overall cancer referrals, during the COVIDâ€19 pandemic. British Journal of Dermatology, 2020, 183, 792-794.	1.4	58
57	The role of the interleukinâ€23/Th17 pathway in cardiometabolic comorbidity associated with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1695-1706.	1.3	57
58	Fiveâ€year efficacy and safety of tildrakizumab in patients with moderateâ€toâ€severe psoriasis who respond at week 28: pooled analyses of two randomized phase III clinical trials (reSURFACE 1 and reSURFACE 2)*. British Journal of Dermatology, 2021, 185, 323-334.	1.4	55
59	Cross-phenotype association mapping of the MHC identifies genetic variants that differentiate psoriatic arthritis from psoriasis. Annals of the Rheumatic Diseases, 2017, 76, 1774-1779.	0.5	51
60	Patterns of biologic therapy use in the management of psoriasis: cohort study from the British Association of Dermatologists Biologic Interventions Register (BADBIR). British Journal of Dermatology, 2017, 176, 1297-1307.	1.4	50
61	Biologic therapies for psoriasis: practical experience in a U.K. tertiary referral centre. British Journal of Dermatology, 2009, 160, 162-169.	1.4	48
62	Barriers to the prescription of systemic therapies for moderate-to-severe psoriasisâ€“â€“a multinational cross-sectional study. Archives of Dermatological Research, 2013, 305, 899-907.	1.1	48
63	One SNP at a Time: Moving beyond GWAS in Psoriasis. Journal of Investigative Dermatology, 2016, 136, 567-573.	0.3	48
64	Risk of tuberculosis reactivation with interleukin (IL)â€17 and ILâ€23 inhibitors in psoriasis â€“ time for a paradigm change. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 824-834.	1.3	48
65	Phenotypic switch to eczema in patients receiving biologics for plaque psoriasis: a systematic review. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1440-1448.	1.3	47
66	Melanoma Risk in Patients Treated With Biologic Therapy for Common Inflammatory Diseases. JAMA Dermatology, 2020, 156, 787.	2.0	45
67	The use of ustekinumab in autoimmune disease. Expert Opinion on Biological Therapy, 2010, 10, 587-604.	1.4	44
68	Loss-of-Function Myeloperoxidase Mutations Are Associated with Increased Neutrophil Counts and Pustular Skin Disease. American Journal of Human Genetics, 2020, 107, 539-543.	2.6	44
69	Matching-adjusted indirect comparison of efficacy in patients with moderate-to-severe plaque psoriasis treated with ixekizumab vs. secukinumab. British Journal of Dermatology, 2018, 178, 1064-1071.	1.4	43
70	Patient perceptions of clear/almost clear skin in moderateâ€toâ€severe plaque psoriasis: results of the Clear About Psoriasis worldwide survey. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2200-2207.	1.3	42
71	Polymorphisms in the PTPN22 region are associated with psoriasis of early onset. British Journal of Dermatology, 2008, 158, 962-968.	1.4	41
72	Exome-wide association study reveals novel psoriasis susceptibility locus at TNFSF15 and rare protective alleles in genes contributing to type I IFN signalling. Human Molecular Genetics, 2017, 26, 4301-4313.	1.4	41

#	Article	IF	Citations
73	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. Annals of the Rheumatic Diseases, 2012, 71, 1350-1354.	0.5	39
74	In search of oral psoriasis. Archives of Dermatological Research, 2012, 304, 1-5.	1.1	39
75	Expression of microRNAâ€184 in keratinocytes represses argonaute 2. Journal of Cellular Physiology, 2013, 228, 2314-2323.	2.0	39
76	Ixekizumab for the treatment of psoriasis: up-to-date. Expert Opinion on Biological Therapy, 2020, 20, 549-557.	1.4	39
77	Rapid Response of Biologic Treatments of Moderate-to-Severe Plaque Psoriasis: A Comprehensive Investigation Using Bayesian and Frequentist Network Meta-analyses. Dermatology and Therapy, 2020, 10, 73-86.	1.4	38
78	Twice-weekly topical calcipotriene/betamethasone dipropionate foam as proactive management of plaque psoriasis increases time in remission and is well tolerated over 52Âweeks (PSO-LONG trial). Journal of the American Academy of Dermatology, 2021, 84, 1269-1277.	0.6	38
79	Comparison of cumulative clinical benefits of biologics for the treatment of psoriasis over 16Âweeks: Results from a network meta-analysis. Journal of the American Academy of Dermatology, 2020, 82, 1138-1149.	0.6	37
80	A Topical Treatment Optimization Programme (TTOP) improves clinical outcome for calcipotriol/betamethasone gel in psoriasis: results of a 64-week multinational randomized phase IV study in 1790 patients (PSO-TOP). British Journal of Dermatology, 2017, 177, 197-205.	1.4	36
81	Infliximab is associated with an increased risk of serious infection in patients with psoriasis in the U.K. and Republic of Ireland: results from the British Association of Dermatologists Biologic Interventions Register (<scp>BADBIR</scp>). British Journal of Dermatology, 2019, 180, 329-337.	1.4	36
82	Association of Toll-like receptor 4 (TLR4) with chronic plaque type psoriasis and psoriatic arthritis. Archives of Dermatological Research, 2016, 308, 201-205.	1.1	35
83	Practical experience of ustekinumab in the treatment of psoriasis: experience from a multicentre, retrospective case cohort study across the U.K. and Ireland. British Journal of Dermatology, 2012, 166, 189-195.	1.4	34
84	Novel Oral Therapies for Psoriasis and Psoriatic Arthritis. American Journal of Clinical Dermatology, 2016, 17, 191-200.	3.3	34
85	Early- and late-onset psoriasis: a cross-sectional clinical and immunocytochemical investigation. British Journal of Dermatology, 2016, 175, 1038-1044.	1.4	33
86	Safety of biological therapies for psoriasis: effects on reproductive potential and outcomes in male and female patients. British Journal of Dermatology, 2014, 171, 485-491.	1.4	32
87	Longâ€term efficacy and safety of secukinumab in the treatment of the multiple manifestations of psoriatic disease. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 1161-1173.	1.3	32
88	Establishing an Academicâ€“Industrial Stratified Medicine Consortium: Psoriasis Stratification to Optimize Relevant Therapy. Journal of Investigative Dermatology, 2015, 135, 2903-2907.	0.3	30
89	Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis. JAMA Dermatology, 2019, 155, 1235.	2.0	30
90	A Framework for Multi-Omic Prediction ofÂTreatment Response to Biologic TherapyÂfor Psoriasis. Journal of Investigative Dermatology, 2019, 139, 100-107.	0.3	30

#	Article	IF	Citations
91	Antibody responses to singleâ€dose SARSâ€CoVâ€2 vaccination in patients receiving immunomodulators for immuneâ€mediated inflammatory disease. British Journal of Dermatology, 2021, 185, 646-648.	1.4	30
92	The Latest Advances in Pharmacogenetics and Pharmacogenomics in the Treatment of Psoriasis. Molecular Diagnosis and Therapy, 2010, 14, 81-93.	1.6	29
93	A systematic investigation of confirmed autoimmune loci in early-onset psoriasis reveals an association with IL2/IL21. British Journal of Dermatology, 2011, 164, no-no.	1.4	28
94	The potential of pharmacogenetics in optimizing the use of methotrexate for psoriasis. British Journal of Dermatology, 2005, 153, 869-873.	1.4	27
95	Risk of major cardiovascular events in patients with psoriasis receiving biologic therapies: a prospective cohort study. Journal of the European Academy of Dermatology and Venereology, 2020, 34, 769-778.	1.3	27
96	Polymorphisms in IL-1B Distinguish between Psoriasis of Early and Late Onset. Journal of Investigative Dermatology, 2014, 134, 1459-1462.	0.3	26
97	Secukinumab reâ€initiation achieves regain of high response levels in patients who interrupt treatment for moderate to severe plaque psoriasis. British Journal of Dermatology, 2017, 177, 879-881.	1.4	26
98	Risk of hospitalization and death due to infection in people with psoriasis: a populationâ€based cohort study using the Clinical Practice Research Datalink*. British Journal of Dermatology, 2021, 184, 78-86.	1.4	26
99	Riskâ€mitigating behaviours in people with inflammatory skin and joint disease during the COVIDâ€19 pandemic differ by treatment type: a crossâ€sectional patient survey*. British Journal of Dermatology, 2021, 185, 80-90.	1.4	26
100	Genotyping of immune-related genetic variants identifiesTYK2as a novel associated locus for idiopathic inflammatory myopathies. Annals of the Rheumatic Diseases, 2014, 73, 1750-1752.	0.5	25
101	Clinical Disease Measures in Generalized Pustular Psoriasis. American Journal of Clinical Dermatology, 2022, 23, 39-50.	3.3	25
102	Treating moderate to severe psoriasis â€“ best use of biologics. Expert Review of Clinical Immunology, 2014, 10, 269-279.	1.3	24
103	The risk of postâ€operative complications in psoriasis and psoriatic arthritis patients on biologic therapy undergoing surgical procedures. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 86-91.	1.3	24
104	Calcipotriol Plus Betamethasone Dipropionate Aerosol Foam in Patients with Moderate-to-Severe Psoriasis: Sub-Group Analysis of the PSO-ABLE Study. American Journal of Clinical Dermatology, 2017, 18, 405-411.	3.3	24
105	Comparative effectiveness of biological therapies on improvements in quality of life in patients with psoriasis. British Journal of Dermatology, 2017, 177, 1410-1421.	1.4	24
106	Adalimumab for psoriasis: practical experience in a U.K. tertiary referral centre. British Journal of Dermatology, 2010, 163, 859-862.	1.4	23
107	Comprehensive longâ€term safety of adalimumab from 18 clinical trials in adult patients with moderateâ€toâ€severe plaque psoriasis. British Journal of Dermatology, 2019, 180, 76-85.	1.4	23
108	Enhanced NF-ÎºB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis. Nature Communications, 2021, 12, 4741.	5.8	23

#	Article	IF	Citations
109	Impact of Disease Severity, Illness Beliefs, and Coping Strategies on Outcomes in Psoriatic Arthritis. Arthritis Care and Research, 2018, 70, 295-302.	1.5	22
110	Anakinra for palmoplantar pustulosis: results from a randomized, doubleâ€blind, multicentre, twoâ€stage, adaptive placeboâ€controlled trial (APRICOT)*. British Journal of Dermatology, 2022, 186, 245-256.	1.4	22
111	Bimekizumab Safety in Patients With Moderate to Severe Plaque Psoriasis. JAMA Dermatology, 2022, 158, 735.	2.0	22
112	Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-Analysis. Dermatology and Therapy, 2022, 12, 1777-1792.	1.4	22
113	Development and Testing of New Candidate Psoriatic Arthritis Screening Questionnaires Combining Optimal Questions From Existing Tools. Arthritis Care and Research, 2014, 66, 1410-1416.	1.5	21
114	Secukinumab for patients failing previous tumour necrosis factorâ€± inhibitor therapy: results of a randomized openâ€label study (SIGNATURE). British Journal of Dermatology, 2020, 183, 60-70.	1.4	21
115	POS1042â€…EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE TYROSINE KINASE 2 (TYK2) INHIBITOR, COMPARED WITH PLACEBO AND APREMILAST IN MODERATE TO SEVERE PLAQUE PSORIASIS: RESULTS FROM THE PHASE 3 POETYK PSO-1 STUDY. Annals of the Rheumatic Diseases, 2021, 80, 795.1-796.	0.5	21
116	Single-cell analysis implicates TH17-to-TH2 cell plasticity in the pathogenesis of palmoplantar pustulosis. Journal of Allergy and Clinical Immunology, 2022, 150, 882-893.	1.5	21
117	The spectrum of oculocutaneous disease. Journal of the American Academy of Dermatology, 2014, 70, 795.e1-795.e25.	0.6	20
118	Efficacy of a fixed combination of calcipotriol/betamethasone dipropionate topical gel in adult patients with mild to moderate psoriasis: blinded interim analysis of a phase IV , multicenter, randomized, controlled, prospective study. Journal of the European Academy of Dermatology and Venereology, 2015, 29, 1156-1163.	1.3	20
119	Long-term control of recalcitrant psoriasis with combination infliximab and methotrexate. Clinical and Experimental Dermatology, 2009, 34, 415-416.	0.6	19
120	Mapping DNA interaction landscapes in psoriasis susceptibility loci highlights KLF4 as a target gene in 9q31. BMC Biology, 2020, 18, 47.	1.7	19
121	Chromatin Looping Links Target Genes with Genetic Risk Loci for Dermatological Traits. Journal of Investigative Dermatology, 2021, 141, 1975-1984.	0.3	19
122	Psoriatic arthritis â€“ what the dermatologist needs to know. Journal of the European Academy of Dermatology and Venereology, 2010, 24, 1270-1277.	1.3	18
123	The Future of Biological Therapies. Seminars in Cutaneous Medicine and Surgery, 2010, 29, 63-66.	1.6	18
124	Efficacy and safety of emerging immunotherapies in psoriasis. Immunotherapy, 2015, 7, 119-133.	1.0	18
125	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. Lancet, The, 2015, 385, S48.	6.3	18
126	Identification of factors that may influence the selection of firstâ€line biological therapy for people with psoriasis: a prospective, multicentre cohort study. British Journal of Dermatology, 2017, 177, 828-836.	1.4	18

#	Article	IF	Citations
127	Association of Clinical and Demographic Factors With the Severity of Palmoplantar Pustulosis. JAMA Dermatology, 2020, 156, 1216.	2.0	18
128	Global reporting of cases of COVIDâ€19 in psoriasis and atopic dermatitis: an opportunity to inform care during a pandemic. British Journal of Dermatology, 2020, 183, 404-406.	1.4	18
129	Real-World Experience and Laboratory Monitoring of Dupilumab in Patients with Moderate to Severe Atopic Dermatitis in a Tertiary Centre. Dermatology and Therapy, 2021, 11, 149-160.	1.4	18
130	Describing the burden of the COVIDâ€19 pandemic in people with psoriasis: findings from a global crossâ€sectional study. Journal of the European Academy of Dermatology and Venereology, 2021, 35, e636-e640.	1.3	18
131	Identification of loci associated with late-onset psoriasis using dense genotyping of immune-related regions. British Journal of Dermatology, 2015, 172, 933-939.	1.4	17
132	Longâ€term safety of certolizumab pegol in plaque psoriasis: pooled analysis over 3 years from three phase III, randomized, placeboâ€controlled studies. British Journal of Dermatology, 2021, 184, 640-651.	1.4	16
133	Precalcaneal Congenital Fibrolipomatous Hamartoma. Pediatric Dermatology, 2007, 24, 74-75.	0.5	15
134	A novel mutation in <scp>IL</scp>36<scp>RN</scp> underpins childhood pustular dermatosis. Journal of the European Academy of Dermatology and Venereology, 2016, 30, 302-305.	1.3	15
135	A small population, randomised, placebo-controlled trial to determine the efficacy of anakinra in the treatment of pustular psoriasis: study protocol for the APRICOT trial. Trials, 2018, 19, 465.	0.7	15
136	A standardization approach to compare treatment safety and effectiveness outcomes between clinical trials and realâ€world populations in psoriasis. British Journal of Dermatology, 2019, 181, 1265-1271.	1.4	15
137	Longâ€term efficacy of certolizumab pegol for the treatment of plaque psoriasis: 3â€year results from two randomized phase III trials (CIMPASIâ€1 and CIMPASIâ€2). British Journal of Dermatology, 2021, 184, 652-662.	1.4	15
138	Time to relapse after tildrakizumab withdrawal in patients with moderateâ€toâ€severe psoriasis who were responders at week 28: post hoc analysis through 64Âweeks from reSURFACE 1 trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 919-927.	1.3	15
139	Porokeratotic Eccrine Ostial and Dermal Duct Nevus. Pediatric Dermatology, 2006, 23, 465-466.	0.5	14
140	Genetic susceptibility to psoriasis: an emerging picture. Genome Medicine, 2009, 1, 72.	3.6	14
141	Research Techniques Made Simple: Bioinformatics for Genome-Scale Biology. Journal of Investigative Dermatology, 2017, 137, e163-e168.	0.3	14
142	Persistence and effectiveness of nonbiologic systemic therapies for moderateâ€toâ€severe psoriasis in adults: a systematic review. British Journal of Dermatology, 2019, 181, 256-264.	1.4	14
143	Complete clearance and psoriasis area and severity index response for brodalumab and ustekinumab in AMAGINEâ€2 and â€3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 450-457.	1.3	14
144	Randomized Trial Replication Using Observational Data for Comparative Effectiveness of Secukinumab and Ustekinumab in Psoriasis. JAMA Dermatology, 2021, 157, 66.	2.0	14

#	Article	IF	Citations
145	Pharmacogenomics and the Resulting Impact on Psoriasis Therapies. Dermatologic Clinics, 2015, 33, 149-160.	1.0	13
146	Network metaâ€analysis of biologic treatments for psoriasis using absolute Psoriasis Area and Severity Index values â‰¤1, 2, 3 or 5 derived from a statistical conversion method. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 1161-1175.	1.3	13
147	Risk of COVIDâ€19 infection in adult patients with atopic eczema and psoriasis: a singleâ€centre crossâ€sectional study. British Journal of Dermatology, 2021, 185, 441-443.	1.4	13
148	Etanercept-induced dermatitis in a patient with rheumatoid arthritis. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 614-615.	1.3	12
149	Topical Treatments for Scalp Psoriasis. Drugs, 2008, 68, 2293-2302.	4.9	12
150	Impact of ixekizumab treatment on skinâ€related personal relationship difficulties in moderateâ€toâ€severe psoriasis patients: 12â€week results from two Phase 3 trials. Journal of the European Academy of Dermatology and Venereology, 2017, 31, 1867-1875.	1.3	12
151	Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy. British Journal of Dermatology, 2019, 180, 894-901.	1.4	12
152	Addressing challenges associated with longâ€term topical treatment and benefits of proactive management in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 35-41.	1.3	12
153	Ustekinumab for the treatment of psoriasis. Seminars in Cutaneous Medicine and Surgery, 2018, 37, 143-147.	1.6	12
154	Depression and Suicidality in Patients With Psoriasis and the Role of Psoriatic Arthritis: AÂCross-sectional Study in a Tertiary Setting. Journal of the Academy of Consultation-Liaison Psychiatry, 2022, 63, 372-383.	0.2	12
155	International eDelphi Study to Reach Consensus on the Methotrexate Dosing Regimen in Patients With Psoriasis. JAMA Dermatology, 2022, 158, 561.	2.0	12
156	Emerging Therapies for the Treatment of Psoriasis. Dermatology and Therapy, 2012, 2, 16.	1.4	11
157	An investigation of rheumatoid arthritis loci in patients with early-onset psoriasis validates association of theRELgene. British Journal of Dermatology, 2013, 168, 864-866.	1.4	11
158	CutaneousMycobacterium haemophiluminfection in a patient receiving infliximab for psoriasis. British Journal of Dermatology, 2013, 168, 446-447.	1.4	11
159	The spectrum of oculocutaneous disease. Journal of the American Academy of Dermatology, 2014, 70, 821.e1-821.e19.	0.6	11
160	Safety of conventional systemic therapies for psoriasis on reproductive potential and outcomes. Journal of Dermatological Treatment, 2015, 26, 329-334.	1.1	11
161	Assessment of two screening tools to identify psoriatic arthritis in patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 1530-1534.	1.3	11
162	Differences in Clinical Features and Comorbid Burden between HLA-Câˆ—06:02 Carrier Groups in >9,000 People with Psoriasis. Journal of Investigative Dermatology, 2022, 142, 1617-1628.e10.	0.3	11

#	Article	IF	Citations
163	Vaccine hesitancy and access to psoriasis care during the <scp>COVID</scp> â€19 pandemic: findings from a global patientâ€reported crossâ€sectional survey. British Journal of Dermatology, 2022, 187, 254-256.	1.4	11
164	Longâ€term, durable, absolute Psoriasis Area and Severity Index and healthâ€related quality of life improvements with risankizumab treatment: a post hoc integrated analysis of patients with moderateâ€toâ€severe plaque psoriasis. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 855-865.	1.3	11
165	Whatâ€™s new in psoriasis? An analysis of guidelines and systematic reviews published in 2009-2010. Clinical and Experimental Dermatology, 2011, 36, 585-589.	0.6	10
166	Application of information theoretic feature selection and machine learning methods for the development of genetic risk prediction models. Scientific Reports, 2021, 11, 23335.	1.6	10
167	Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis. Advances in Therapy, 2022, 39, 2256-2269.	1.3	10
168	A case of recalcitrant necrobiosis lipoidica responding to combined immunosuppression therapy. Journal of the European Academy of Dermatology and Venereology, 2007, 21, 830-831.	1.3	9
169	Ustekinumab for the treatment of psoriasis. Expert Review of Clinical Immunology, 2011, 7, 155-164.	1.3	9
170	Psoriasis and susceptibility to other autoimmune diseases: an outline for the clinician. Expert Review of Clinical Immunology, 2013, 9, 99-101.	1.3	9
171	Development of chronic inflammatory demyelinating polyneuropathy in a patient receiving infliximab for psoriasis. British Journal of Dermatology, 2014, 170, 206-209.	1.4	9
172	Genotypic variability-based genome-wide association study identifies non-additive loci HLA-C and IL12B for psoriasis. Journal of Human Genetics, 2018, 63, 289-296.	1.1	9
173	Progress to Date in Advancing Stratified Medicine in Psoriasis. American Journal of Clinical Dermatology, 2020, 21, 619-626.	3.3	9
174	Using Realâ€World Data to Guide Ustekinumab Dosing Strategies for Psoriasis: A Prospective Pharmacokineticâ€Pharmacodynamic Study. Clinical and Translational Science, 2020, 13, 400-409.	1.5	9
175	Secukinumab significantly reduces psoriasisâ€related work impairment and indirect costs compared with ustekinumab and etanercept in the United Kingdom. Journal of the European Academy of Dermatology and Venereology, 2018, 32, 2178-2184.	1.3	8
176	Assessing the Quality and Coherence of Network Meta-Analyses of Biologics in Plaque Psoriasis: What Does All This Evidence Synthesis Tell Us?. Dermatology and Therapy, 2021, 11, 181-220.	1.4	8
177	Paradoxical eczema in patients with psoriasis receiving biologics: a case series. Clinical and Experimental Dermatology, 2022, 47, 1174-1178.	0.6	8
178	Longâ€term efficacy and safety of brodalumab in moderateâ€toâ€severe plaque psoriasis: a post hoc pooled analysis of AMAGINEâ€2 and â€3. Journal of the European Academy of Dermatology and Venereology, 2022, 36, 1275-1283.	1.3	8
179	Whatâ€™s new in psoriasis? Analysis of the clinical significance of systematic reviews on psoriasis published in 2007 and 2008. Clinical and Experimental Dermatology, 2009, 34, 664-667.	0.6	7
180	National and multinational guidelines in Europe: results from an online survey on awareness of different national and European psoriasis guidelines. Archives of Dermatological Research, 2013, 305, 637-643.	1.1	7

#	Article	IF	Citations
181	Time for a â€˜jointâ€™ approach?. British Journal of Dermatology, 2013, 168, 683-684.	1.4	7
182	SAT0052â€…Influence of Immunogenicity and Drug Levels on the Efficacy of Long-Term Treatment of Rheumatoid Arthritis with Adalimumab and Etanercept: A Uk-Based Prospective Study. Annals of the Rheumatic Diseases, 2014, 73, 608.1-608.	0.5	7
183	Re: Quantitative Evaluation of Biologic Therapy Options for Psoriasis: A Systematic Review and Network Meta-Analysis. Journal of Investigative Dermatology, 2017, 137, 2644-2646.	0.3	7
184	Clinical response of psoriasis to subcutaneous methotrexate correlates with inhibition of cutaneous T helper 1 and 17 inflammatory pathways. British Journal of Dermatology, 2019, 181, 859-862.	1.4	7
185	A randomised placebo controlled trial of anakinra for treating pustular psoriasis: statistical analysis plan for stage two of the APRICOT trial. Trials, 2020, 21, 158.	0.7	7
186	Efficacy of Risankizumab versus Secukinumab in Patients with Moderate-to-Severe Psoriasis: Subgroup Analysis from the IMMerge Study. Dermatology and Therapy, 2022, 12, 561-575.	1.4	7
187	No Association between Polymorphisms in the Interleukin-15 Gene and Early-Onset Psoriasis in a UK Cohort Suggests Heterogeneity for this Susceptibility Locus Identified in Chinese Psoriasis Patients. Journal of Investigative Dermatology, 2008, 128, 2904-2905.	0.3	6
188	Recall injection-site reactions to etanercept in a patient with psoriasis. Clinical and Experimental Dermatology, 2009, 34, 414-415.	0.6	6
189	Whatâ€™s new in psoriasis? Analysis of the clinical significance of new guidelines and systematic reviews on psoriasis published in 2008 and 2009. Clinical and Experimental Dermatology, 2010, 35, 688-692.	0.6	6
190	Re. major lifeâ€changing decisions and cumulative life course impairment. Journal of the European Academy of Dermatology and Venereology, 2011, 25, 246-246.	1.3	6
191	The potential utility of tildrakizumab: an interleukin-23 inhibitor for the treatment of psoriasis. Expert Opinion on Investigational Drugs, 2017, 26, 243-249.	1.9	6
192	OP0108â€…DUAL NEUTRALISATION OF IL-17A AND IL-17F WITH BIMEKIZUMAB IN PATIENTS WITH ACTIVE PSA: OVERALL AND TNF-INHIBITOR-NAÃVE POPULATION RESULTS FROM A 48-WEEK PHASE 2B RANDOMISED STUDY. , 2019, , .		6
193	PSO-LONG: Design of a Novel, 12-Month Clinical Trial of Topical, Proactive Maintenance with Twice-Weekly Cal/BD Foam in Psoriasis. Advances in Therapy, 2020, 37, 4730-4753.	1.3	6
194	Development and Content Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM) for Assessment of Plaque Psoriasis. Dermatology and Therapy, 2020, 10, 1255-1272.	1.4	6
195	Clinical Impact of Antibodies against Ustekinumab in Psoriasis: An Observational, Cross-Sectional, Multicenter Study. Journal of Investigative Dermatology, 2020, 140, 2129-2137.	0.3	6
196	Complete clearance and Psoriasis Area and Severity Index response for brodalumab and ustekinumab by previous treatment history in AMAGINEâ€2 and AMAGINEâ€3. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2034-2044.	1.3	6
197	Effectiveness of Subcutaneous Methotrexate in Chronic Plaque Psoriasis. Journal of Drugs in Dermatology, 2016, 15, 345-9.	0.4	6
198	A Practical Guide to the Management of Oral Candidiasis in Patients with Plaque Psoriasis Receiving Treatments That Target Interleukin-17. Dermatology and Therapy, 2022, 12, 787-800.	1.4	6

#	Article	IF	Citations
199	What's new in psoriasis treatment? An analysis of systematic reviews published in 2015. Clinical and Experimental Dermatology, 2018, 43, 759-765.	0.6	5
200	Feasibility and Utility of the Psoriasis Symptom Inventory (PSI) in Clinical Care Settings: A Study from the International Psoriasis Council. American Journal of Clinical Dermatology, 2019, 20, 699-709.	3.3	5
201	Update on risankizumab for the treatment of moderate to severe psoriasis. Expert Opinion on Biological Therapy, 2020, 20, 1245-1251.	1.4	5
202	How is safety of dermatology drugs assessed: trials, registries, and spontaneous reporting. Expert Opinion on Drug Safety, 2020, 19, 449-457.	1.0	5
203	POS1022â€...BIMEKIZUMAB SAFETY AND EFFICACY IN PATIENTS WITH PSORIATIC ARTHRITIS: 3-YEAR RESULTS FROM A PHASE 2b OPEN-LABEL EXTENSION STUDY. Annals of the Rheumatic Diseases, 2021, 80, 779-780.	0.5	5
204	Bimekizumab: a dual IL-17A and IL-17F inhibitor for the treatment of psoriasis and psoriatic arthritis. Expert Review of Clinical Immunology, 2021, 17, 1073-1081.	1.3	5
205	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM): A Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Reported Data from the BE RADIANT Phase 3b Trial. Advances in Therapy, 2021, 38, 5253-5269.	1.3	5
206	A case of CD8+ small/medium-sized pleomorphic T-cell lymphoma: clinical and histopathological differential diagnosis. British Journal of Dermatology, 2014, 170, 204-206.	1.4	4
207	Guselkumab for psoriasis: a critical appraisal of Phase III studies. Immunotherapy, 2018, 10, 67-75.	1.0	4
208	Longâ€term, realâ€world efficacy of biologics for psoriasis: a single centre's experience. British Journal of Dermatology, 2019, 181, 599-601.	1.4	4
209	An evaluation of dermatology patients shielding during the COVIDâ€19 outbreak. Clinical and Experimental Dermatology, 2021, 46, 193-194.	0.6	4
210	Defining trajectories of response in patients with psoriasis treated with biologic therapies. British Journal of Dermatology, 2021, 185, 825-835.	1.4	4
211	Psychometric Validation of the Psoriasis Symptoms and Impacts Measure (P-SIM), a Novel Patient-Reported Outcome Instrument for Patients with Plaque Psoriasis, Using Data from the BEÂVIVID and BEÂREADY PhaseÂ3 Trials. Dermatology and Therapy, 2021, 11, 1551-1569.	1.4	4
212	Meeting Report: Psoriasis Stratification to Optimize Relevant Therapy Showcase. Journal of Investigative Dermatology, 2021, 141, 1872-1878.	0.3	4
213	Threeâ€year efficacy and safety of certolizumab pegol for the treatment of plaque psoriasis: results from the randomized phase 3 CIMPACT trial. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 2398-2408.	1.3	4
214	Treatment of severe psoriasis with biological therapies in patients with viral hepatitis B and C. British Journal of Dermatology, 2013, 168, 461-462.	1.4	3
215	Patients' Narratives. Current Problems in Dermatology, 2013, 44, 145-157.	0.8	3
216	Switching from a fumaric acid ester mixture to dimethylfumarate monotherapy in psoriasis. Journal of the European Academy of Dermatology and Venereology, 2019, 33, e352-e353.	1.3	3

#	Article	IF	Citations
217	Long-Term Proactive Treatment of Plaque Psoriasis with Calcipotriene/Betamethasone Dipropionate Foam Prolongs Remission and Reduces Relapses Irrespective of Patient Baseline Characteristics. Dermatology and Therapy, 2021, 11, 1657-1665.	1.4	3
218	Ustekinumab for psoriatic arthritis: close to the PSUMMIT?. Lancet, The, 2013, 382, 748-749.	6.3	2
219	Reply to â€˜Impact of biologic therapies on risk of major adverse cardiovascular events in patients with psoriasis: systematic review and meta-analysis of randomized controlled trialsâ€™: reply from the authors. British Journal of Dermatology, 2017, 177, 1766-1767.	1.4	2
220	Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist. Clinical Pharmacology and Therapeutics, 2017, 102, 642-648.	2.3	2
221	The Potential Benefits of Certolizumab Pegol in Patients with Concurrent Psoriatic Arthritis and Chronic Plaque Psoriasis: A Case Series and Review of the Literature. Dermatology and Therapy, 2019, 9, 373-381.	1.4	2
222	Ixekizumab treatment and the impact on SF-36: results from three pivotal phase III randomised controlled trials in patients with moderate-to-severe plaque psoriasis. Quality of Life Research, 2020, 29, 369-380.	1.5	2
223	A rapid access clinic for psoriasis: first experiences. British Journal of Dermatology, 2022, 187, 426-428.	1.4	2
224	Associations between psoriatic arthritis and mental health among patients with psoriasis: A replication and extension study using the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR). Skin Health and Disease, 0, , .	0.7	2
225	Future Therapeutic Directions for the Treatment of Psoriasis. Actas Dermo-sifiliogrÃ¡ficas, 2009, 100, 28-31.	0.2	1
226	Unmasking of axial spondyloarthritis and oligoarthritis following discontinuation of tumour necrosis factor inhibitor therapy for psoriasis. Journal of Dermatological Treatment, 2014, 25, 61-62.	1.1	1
227	AB0727â€…Increased Rates of Hypertension in Patients with Psoriatic Arthritis Compared To Psoriasis Alone: Results from The UK Biobank: Table 1.. Annals of the Rheumatic Diseases, 2016, 75, 1153.1-1153.	0.5	1
228	A Summary of 2018 and What Lies Ahead for Dermatology and Therapy in 2019. Dermatology and Therapy, 2019, 9, 1-3.	1.4	1
229	Longâ€term safety of adalimumab in adult patients with plaque psoriasis. British Journal of Dermatology, 2019, 180, e13-e13.	1.4	1
230	Risankizumab vs. adalimumab for moderateâ€toâ€severe plaque psoriasis: a critical appraisal. British Journal of Dermatology, 2020, 183, 220-221.	1.4	1
231	Adalimumab for the treatment of psoriasis. Expert Review of Dermatology, 2009, 4, 15-21.	0.3	1
232	Remote consultations: an audit of the management of dermatology patients on biologics during the first wave of the COVID-19 pandemic. Journal of Dermatological Treatment, 2022, 33, 2697-2697.	1.1	1
233	The interleukin 1 receptor antagonist anakinra to reduce disease severity of palmoplantar pustulosis in adults: APRICOT RCT and PLUM mechanistic study. Efficacy and Mechanism Evaluation, 2022, 9, 1-106.	0.9	1
234	The effect of the Covidâ€19 pandemic on illness perceptions of psoriasis and the role of depression: Findings from a crossâ€sectional study. Skin Health and Disease, 0, , .	0.7	1

#	Article	IF	Citations
235	Identity of singleâ€nucleotide polymorphisms used in a clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy: Comment on the article by Wessels et al. Arthritis and Rheumatism, 2008, 58, 1204-1205.	6.7	0
236	Systemic therapies containing ethanol and gelatine excipients. British Journal of Dermatology, 2010, 163, 885-886.	1.4	0
237	Psoriasis comorbidities: a worldwide problem?. British Journal of Dermatology, 2011, 165, 929-929.	1.4	0
238	Letter from the Editors. Dermatology and Therapy, 2011, 1, 1-1.	1.4	0
239	Dermatology: Future Therapeutic Perspectives. Dermatology and Therapy, 2013, 3, 115-116.	1.4	0
240	Psoriatic arthritis screening tools: study design and methodologic challenges - reply from authors. British Journal of Dermatology, 2014, 170, 995-996.	1.4	0
241	AB0115â€…Comparison of the bacterial stool microbiota in established psoriatic arthritis (PSA) and psoriasis (PSC) - exploratory analysis of pilot data. , 2017, , .		0
242	FRI0004â€…CHROMATIN INTERACTIONS IN NOVEL CELL TYPES REVEAL PARK7 AND ERRFI1 AS PUTATIVE CAUSAL GENES IN THE SUSCEPTIBILITY TO PSORIATIC ARTHRITIS. , 2019, , .		0
243	Editorial: fixedâ€dose combination calcipotriol/betamethasone dipropionate foam in the treatment of patients with psoriasis. Journal of the European Academy of Dermatology and Venereology, 2021, 35, 3-4.	1.3	0
244	Psoriasis and Comorbidities. , 2021, , 363-397.		0
245	Secukinumab improves the qualityâ€ofâ€life of family members and partners of people with psoriasis: Family Dermatology Life Quality Index (FDLQI) results from a randomised openâ€label study (SIGNATURE). , 2022, 1, 207-218.		0